These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32804742)

  • 1. Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
    Papakostas GI; Fava M; Freeman MP; Shelton RC; Thase ME; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
    Int Clin Psychopharmacol; 2020 Nov; 35(6):313-321. PubMed ID: 32804742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
    Freeman MP; Fava M; Dirks B; Jha MK; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
    Depress Anxiety; 2020 May; 37(5):485-495. PubMed ID: 32301591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
    Jha MK; Fava M; Freeman MP; Thase ME; Papakostas GI; Shelton RC; Trivedi MH; Dirks B; Liu K; Stankovic S
    J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33264819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
    Fava M; Dirks B; Freeman MP; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
    J Clin Psychiatry; 2019 Sep; 80(6):. PubMed ID: 31556975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.
    Soogrim V; Ruberto VL; Murrough J; Jha MK
    Drug Des Devel Ther; 2021; 15():151-157. PubMed ID: 33469267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
    Shelton RC; Fava M; Freeman MP; Thase ME; Papakostas GI; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
    J Affect Disord; 2020 Dec; 277():478-485. PubMed ID: 32871535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies.
    Dirks B; Fava M; Atkinson SD; Joyce M; Thase ME; Howell B; Lin T; Stankovic S
    Psychopharmacol Bull; 2022 Oct; 52(4):8-30. PubMed ID: 36339271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder.
    Darwish M; Dirks B; Passarell J; Jaworowicz D; Bihorel S; Howell B; Owen J; DeKarske D; Stankovic S
    Clin Pharmacol Drug Dev; 2023 May; 12(5):463-474. PubMed ID: 36880278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
    DeKarske D; Alva G; Aldred JL; Coate B; Cantillon M; Jacobi L; Nunez R; Norton JC; Abler V
    J Parkinsons Dis; 2020; 10(4):1751-1761. PubMed ID: 32804101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
    Bugarski-Kirola D; Arango C; Fava M; Nasrallah H; Liu IY; Abbs B; Stankovic S
    Lancet Psychiatry; 2022 Jan; 9(1):46-58. PubMed ID: 34861170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
    Kornstein SG; Guico-Pabia CJ; Fayyad RS
    Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication.
    Davis J; Zamora D; Horowitz M; Leucht S
    Expert Opin Pharmacother; 2021 Sep; 22(13):1651-1660. PubMed ID: 34404290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.